Endurance Wealth Management, Inc. Achilles Therapeutics PLC Call Options Transaction History
Endurance Wealth Management, Inc.
- $731 Million
- Q2 2023
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding ACHL
# of Institutions
22Shares Held
24.2MCall Options Held
0Put Options Held
0-
Syncona Portfolio LTD Guernsey, Channel Islands, X011.1MShares$15.2 Million23.86% of portfolio
-
Bml Capital Management, LLC Zionsville, IN4.1MShares$5.62 Million2.9% of portfolio
-
Fcpm Iii Services B.V. Naarden, P72.39MShares$3.27 Million0.46% of portfolio
-
Redmile Group, LLC San Francisco, CA1.61MShares$2.2 Million0.14% of portfolio
-
Vestal Point Capital, LP New York, NY1.5MShares$2.06 Million0.1% of portfolio
About Achilles Therapeutics plc
- Ticker ACHL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,774,000
- Market Cap $55.9M
- Description
- Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...